Board of Directors

Mr. Bruce R. Ross (Chairman)
Bruce R. Ross was appointed Chairman of the Board in January 2006. Mr. Ross is currently President of Cancer Rx, a healthcare-consulting firm. Immediately prior to launching Cancer Rx, Mr. Ross was Chief Executive Officer of the National Comprehensive Cancer Network, an association of 15 of the largest cancer centers in the United States. He previously held senior management positions, during a 27-year career, at Bristol-Myers Squibb, including Senior Vice President, Policy, Planning and Development, Bristol-Myers Squibb Pharmaceutical Group and President, Bristol-Myers Squibb U.S. Pharmaceutical Group. He received his B.S. from Syracuse University and later was a Bristol-Myers Scholar at the Yale School of Organization and Management. Mr. Ross began serving as a Director of IDEC Pharmaceuticals in 1997.

Mr. James C. Mullen
James C. Mullen is President and Chief Executive Officer of Biogen Idec and has served in these positions since the merger in November 2003. Mr. Mullen joined Biogen Inc. in 1989. He was named Chief Executive Officer in 2000 and Chairman in 2002. Prior to being named CEO and Chairman, he also held the positions of President and Chief Operating Officer (1999-2000); Vice President, International (1996-1999); Vice President, Operations (1992-1996); and Director, Facilities and Engineering (1989-1992). Mr. Mullen is a member of the of PerkinElmer Inc. and the Biomedical Science Careers Program Inc. He holds a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute and an M.B.A. from Villanova University.

Mr. Lawrence C. Best
Lawrence C. Best retired in July 2007 as Executive Vice President of Boston Scientific. He was formerly the Executive Vice President for Finance and Administration and Chief Financial Officer of Boston Scientific Corporation and held those positions since 1992. From 1981 to 1992, Mr. Best served as Senior Partner with Ernst & Young. From 1979 to 1981, Mr. Best served as a Professional Accounting Fellow in the Office of the Chief Accountant at the Securities and Exchange Commission. Mr. Best began serving as a Director of Biogen in 2003. He is also a director of Haemonetics Corp.

Mr. Marijn E. Dekkers
Marijn E. Dekkers is President and Chief Executive Officer of Thermo Fisher Scientific Inc. and has served in that position since the merger of Thermo Electron Corp. and Fisher Scientific International in November 2006. Prior to that merger, Mr. Dekkers was President and Chief Executive Officer of Thermo Electron Corp., a position he held since November 2002. He served as Thermos President and Chief Operating Officer from July 2000 to November 2002. Prior to joining Thermo Electron Corp., Mr. Dekkers held various positions of increasing responsibility at Honeywell International Inc. (formerly AlliedSignal Inc.) and General Electric Co. Mr. Dekkers is also a director of Thermo Fisher Scientific.

Alan B. Glassberg, M.D.
Dr. Alan B. Glassberg is a Venture Partner and member of the Scientific Advisory Board of Bay City Capital, a firm that manages investment funds in the life sciences industry. He has been associated with Bay City Capital since 2006. Dr. Glassberg served as Chief Medical Officer of Poniard Pharmaceuticals Inc. from August 2006 to March 2007, and he currently serves as a consultant to Poniard and as a member of its Clinical Advisory Board. Dr. Glassberg was Associate Director of Clinical Care and Director of General Oncology at the University of California San Francisco Cancer Center and Director of Hematology and Medical Oncology at Mount Zion Medical Center in San Francisco until June 2006. He received his M.D. from the Medical University of South Carolina in Charleston. Dr. Glassberg began serving as a Director of IDEC Pharmaceuticals in 1997.

Thomas F. Keller, Ph.D.
Thomas F. Keller, Ph.D., has served as R.J. Reynolds Professor Emeritus of Business Administration and Dean Emeritus of the Fuqua School of Business at Duke University since September 2004. From 1974 to September 2004, Dr. Keller was R.J. Reynolds Professor of Business Administration at Duke University. From 1999 to 2001, Dr. Keller served as Dean of the Fuqua School of Business Europe at Duke. From 1974 to 1996, Dr. Keller served as Dean of the Fuqua School of Business at Duke. Dr. Keller began serving as a Director of Biogen Inc. in 1996. He is also a Director of Wendys International.

Ms. Nancy L. Leaming
Nancy L. Leaming retired in 2005 as President and CEO of Tufts Health Plan. For 20 years, Ms. Leaming served in several executive positions at Tufts Health Plan, including President and CEO (2003 – 2005), President and Chief Operating Officer (1997-2003) and Chief Operating Officer (1986-1997). Ms. Leaming successfully led the managed care company to become a nationally recognized leader in its field, creating a strategic vision and strong corporate culture defined by product innovation, service excellence, quality and patient safety. She has served in various capacities on both commercial and non-profit boards. Ms. Leaming is currently a member of the boards of directors at Hologic Inc., where she chairs the Audit Committee, Edgewater Technology Inc., the Massachusetts Taxpayers Foundation and the American Red Cross of Massachusetts.

Mr. Robert W. Pangia
Robert W. Pangia has worked in investment banking for 20 years and is currently a partner in Ivy Capital Partners LLC and general partner of Ivy Healthcare Capital L.P., a private equity fund specializing in healthcare investments. From 1996 to February 2003, Mr. Pangia was self-employed as an investment banker. From 1987 to 1996, Mr. Pangia held various senior management positions at PaineWebber Inc. including: member of the board of directors, Chairman of the board of directors of PaineWebber Properties Inc., member of PaineWebbers executive and operating committees, Chairman of the equity commitment committee, member of the debt commitment committee and Executive Vice President and Director of Investment Banking for PaineWebber Inc. of New York. Prior to his positions at PaineWebber, Mr. Pangia held other senior positions, including Managing Director of Investment Banking for Drexel Burnham Lambert of New York and Vice President of Investment Banking for Kidder, Peabody & Co. of New York. He received his A.B. from Brown University and his M.B.A. from Columbia University. Mr. Pangia began serving as a Director of IDEC Pharmaceuticals in September 1997. He is also a Director of McAfee Inc.

Cecil Pickett, Ph.D.
Cecil Pickett, Ph.D., has served as President, Research and Development, at Biogen Idec since September 2006. Prior to joining Biogen Idec, Dr. Pickett held several senior R&D; positions, most recently as Corporate Senior Vice President & President, Schering-Plough Research Institute. In this capacity, Dr. Pickett helped bring several large and small molecule candidates into the Schering-Plough clinical development pipeline. Prior to joining Schering-Plough, he held several senior R&D; positions at Merck & Co. Dr. Pickett received his Ph.D. in cell biology from University of California at Los Angeles and his B.Sc. in biology from California State University at Hayward. He began serving as a Director in September 2006.

The Honorable Lynn Schenk
Lynn Schenk is an attorney in private practice. She served as Chief of Staff to the Governor of California from January 1999 to November 2003. Ms. Schenk was previously an attorney in private practice from 1996 to 1998 and from 1983 to 1993. Ms. Schenk served as the U.S. Representative for the 49th District of the State of California from 1993 to 1995 and served as the California Secretary of Business, Transportation and Housing from 1980 to 1983. She received her B.A. in Political Science from the University of California at Los Angeles, earned her J.D. from the University of San Diego and attended the London School of Economics. Ms. Schenk began serving as a Director of IDEC Pharmaceuticals in 1995. She is also a member of the Board of Trustees of The Scripps Research Institute.

Phillip A. Sharp, Ph.D.
Phillip A. Sharp, Ph.D., is Institute Professor at the Massachusetts Institute of Technology and a faculty member in the Department of Biology and the Center for Cancer Research. Dr. Sharp served as Director in the Center for Cancer Research (1985-1991), as Head of the Department of Biology (1991-1999), and more recently as Director of the McGovern Institute for Brain Research (2000-2004) at the Massachusetts Institute of Technology. Dr. Sharp co-founded Biogen Inc. in 1978, served as Chairman of the Scientific Advisory Committee and began serving as a Director in 1982. He is also co-founder (2002), Director and Chairman of the Scientific Advisory Board of Alnylam Pharmaceuticals Inc. and director of Magen BioSciences Inc. Dr. Sharp is a Nobel Laureate and a National Medal of Science recipient.

Mr. William D. Young
William D. Young is Chairman and Chief Executive Officer for Monogram Biosciences Inc. (formerly ViroLogic, Inc.). From 1997 to 1999, Mr. Young served as Chief Operating Officer of Genentech Inc. Mr. Young joined Genentech in 1980 as Director of Manufacturing and Process Sciences and became Vice President in 1983. He was promoted to various positions and, in 1997, became Chief Operating Officer, taking on responsibility for all development, operations and sales and marketing activities. Prior to joining Genentech, Mr. Young was with Eli Lilly & Co. for 14 years. Mr. Young holds a B.S. in Chemical Engineering from Purdue University and a M.B.A. from Indiana University. Mr. Young began serving as a Director of IDEC Pharmaceuticals in 1997. He is also a Director of Monogram Biosciences Inc. and Theravance Inc. Mr. Young was elected to the National Academy of Engineering in 1993 for his contributions to biotechnology.